Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells

  • Authors:
    • Pengzhen Wang
    • Jinli Zhang
    • Xifeng Xiong
    • Wei Yuan
    • Shengnan Qin
    • Wenjuan Cao
    • Libing Dai
    • Fuqin Xie
    • Aiguo Li
    • Zhihe Liu
  • View Affiliations

  • Published online on: January 28, 2019     https://doi.org/10.3892/or.2019.6986
  • Pages: 2321-2328
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer is the third most common type of gynecological tumor, in addition to being the most lethal. Cytoreductive surgery with chemotherapy is the standard treatment for ovarian cancer. It is necessary to identify novel chemotherapeutic methods, since current chemotherapy treatments are rarely effective for patients with advanced‑stage or recurrent ovarian cancer and may cause acute systemic toxicity. Icariin (ICA) is a prenylated flavonol glycoside derived from Herba Epimedii, a medicinal plant with a variety of pharmacological activities, including anticancer, antidiabetic and anti‑obesity effects. By analyzing cell viability, cell cycle and cell migration, the present study demonstrated that ICA inhibited the cell viability of the ovarian cancer cell line, SKOV3, and blocked cell cycle transition. ICA inhibited the expression of fuse binding protein 1 (FBP1), a critical regulator of proliferation and tumorigenesis through binding to the c‑Myc promoter, as well as β‑catenin, a key regulator in ovarian cancer initiation, metastasis, chemoresistance and recurrence. Furthermore, it was indicated that ICA inhibited the migration of SKOV3 cells. In accordance with our previous findings on high FBP1 expression in ovarian cancer, FBP1 was a potential target of ICA in ovarian cancer cells. Based on these results, the present study demonstrated that ICA may be a potential therapeutic agent for ovarian cancer treatment.
View Figures
View References

Related Articles

Journal Cover

April-2019
Volume 41 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang P, Zhang J, Xiong X, Yuan W, Qin S, Cao W, Dai L, Xie F, Li A, Liu Z, Liu Z, et al: Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells. Oncol Rep 41: 2321-2328, 2019
APA
Wang, P., Zhang, J., Xiong, X., Yuan, W., Qin, S., Cao, W. ... Liu, Z. (2019). Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells. Oncology Reports, 41, 2321-2328. https://doi.org/10.3892/or.2019.6986
MLA
Wang, P., Zhang, J., Xiong, X., Yuan, W., Qin, S., Cao, W., Dai, L., Xie, F., Li, A., Liu, Z."Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells". Oncology Reports 41.4 (2019): 2321-2328.
Chicago
Wang, P., Zhang, J., Xiong, X., Yuan, W., Qin, S., Cao, W., Dai, L., Xie, F., Li, A., Liu, Z."Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells". Oncology Reports 41, no. 4 (2019): 2321-2328. https://doi.org/10.3892/or.2019.6986